CAR-T & Cellular Therapy Focus

Explore the latest updates and expert interviews

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech. These supporters have no influence over the production of the content.

Welcome to CAR-T & Cellular Therapy Focus

Explore the latest updates in this field by haematological disease and therapy type, showcasing expert interviews and discussions, podcasts and e-learning.

CAR-T and other cellular therapies are at the frontier of hematological malignancy research, offering the potential for paradigm-changing new treatments. Although various questions remain open, it is essential that healthcare professionals understand these therapies, including recognizing and managing their toxicities, and when and how to use them.

Latest CAR-T and Cellular Therapy Videos

View all
1:35
Patient responses to CAR-T therapy and factors that may influence these responses
Yi Lin • 25 Aug 2022
3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022
2:01
An update on cohort C from the CARTITUDE-2 trial
Adam Cohen • 26 Aug 2022
5:57
Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosis
Moshe Gatt • 5 Sep 2022

View CAR-T and Cellular Therapy Videos by Disease Area

Multiple Myeloma
Lymphoma
ALL
AML
CLL
1:35
Patient responses to CAR-T therapy and factors that may influence these responses
Yi Lin • 25 Aug 2022
3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022
2:01
An update on cohort C from the CARTITUDE-2 trial
Adam Cohen • 26 Aug 2022
3:07
The important role of the multidisciplinary team in CAR-T therapy
Mohamad Mohty • 25 Aug 2022
View All Videos
1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022
5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
3:34
Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphoma
Peihua Lu • 16 Jun 2022
5:29
CD7 gene knockout CAR-T cell therapy for R/R T-cell hematological malignancies
Peihua Lu • 16 Jun 2022
View All Videos
5:14
Novel synthetic TCR and antigen receptor (STAR) T-cell therapy for B-ALL
Peihua Lu • 16 Jun 2022
1:20
Managing relapse after CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022
5:39
Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL
Peihua Lu • 16 Jun 2022
5:29
CD7 gene knockout CAR-T cell therapy for R/R T-cell hematological malignancies
Peihua Lu • 16 Jun 2022
View All Videos
3:47
The role of immunotherapy in the AML treatment landscape
Thomas Cluzeau • 12 Jun 2022
2:40
Recent advances in CAR-T therapy for MDS
David Sallman • 11 Jun 2022
2:33
Promising strategies to optimize CAR-T therapy in ALL
Sara Ghorashian • 12 Jun 2022
3:24
Replacing autoSCT with immunotherapies: pros and cons
Paul Richardson • 14 May 2022
View All Videos
0:55
Acalabrutinib in patients with CLL and MCL undergoing alloSCT
Wojciech Jurczak • 11 Jun 2022
2:14
Ibrutinib’s role in CLL treatment and future outlooks
Toby Eyre • 15 Jun 2022
1:25
Where are we with CAR-T in CLL?
John Gribben • 9 Jun 2022
1:30
Exciting new agents in CLL
John Gribben • 9 Jun 2022
View All Videos

NK-cell therapy

View all
1:30
Advances in immunotherapy for multiple myeloma
Hermann Einsele • 11 Jun 2022
0:40
The current status of CAR T and CAR NK cells in multiple myeloma
Matthew Frigault • 3 Jun 2022
2:45
Challenges faced with the production of universal CAR-T products
Martina Sersch et al. • 14 Apr 2022
1:18
The role of cellular immunotherapies in the future treatment of HL
Yago Nieto • 10 Apr 2022

Features

View all
Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia
Highlights in lymphoid malignancies from EHA 2022
Approval of axi-cel in second-line for R/R LBCL & label update
Ciltacabtagene autoleucel receives FDA approval for R/R multiple myeloma

View CAR-T and Cellular Therapy Videos by Topic

Nursing
Clinical Practice
Policy
Treatment
Toxicity
Manufacturing
0:52
Nursing and CAR-T therapy
John Murray • 22 Mar 2022
2:29
The nurse’s role in CAR-T therapy
Michelle Kenyon • 14 Feb 2022
2:53
Supporting patients during CAR-T therapy
Michelle Kenyon • 14 Feb 2022
3:09
Educating patients and nurses on CAR-T therapy
Michelle Kenyon • 14 Feb 2022
View All Videos
2:52
Managing toxicity post-CAR-T therapy in multiple myeloma
Yi Lin • 25 Aug 2022
2:26
Factors to consider when selecting myeloma patients for antibody therapy
Rakesh Popat • 10 Jun 2022
3:16
The management of high-risk ALL
Arnon Nagler • 12 Jun 2022
2:45
Aims & projects of the GoCART coalition
Christian Chabannon • 11 Jun 2022
View All Videos
1:21
Approval of axi-cel in second-line for R/R LBCL & label update
Evandro Bezerra • 23 Apr 2022
2:38
Tackling inequalities in the field of stem cell transplantation and cellular therapies
Nico Gagelmann • 21 Mar 2022
3:35
Engaging with stakeholders to solve CAR-T supply chain and regulatory issues
Christian Chabannon • 22 Mar 2022
4:38
An update on the EBMT Patient Registry & GoCART
Christian Chabannon • 14 Feb 2022
View All Videos
1:35
Patient responses to CAR-T therapy and factors that may influence these responses
Yi Lin • 25 Aug 2022
3:15
Optimal strategies to manage late-stage multiple myeloma: the promise of anti-BCMA therapies
Salomon Manier • 27 Aug 2022
2:01
An update on cohort C from the CARTITUDE-2 trial
Adam Cohen • 26 Aug 2022
5:57
Feasibility of BCMA-directed CAR-T therapy in R/R AL amyloidosis
Moshe Gatt • 5 Sep 2022
View All Videos
2:26
Factors to consider when selecting myeloma patients for antibody therapy
Rakesh Popat • 10 Jun 2022
1:09
Treatment holidays in multiple myeloma
Graham Jackson • 13 May 2022
1:20
Managing the side effects of CAR-T therapies
Steven Kanner • 10 Apr 2022
2:30
The management of CAR-T related toxicities in leukemia and lymphoma
Marion Subklewe • 21 Mar 2022
View All Videos
3:51
Donor-derived allogeneic CAR-T for B-ALL post-transplant
Claire Roddie • 7 Dec 2019
1:31
The importance of the European Medicines Agency in CAR-T development
Ulrich Jäger
11:58
iwNHL day 2 highlights: bridging the gap to CAR T-cell therapy & precision medicine
Anas Younes et al. • 22 Sep 2018
3:08
Identifying patient subgroups to improve outcome, resistance and toxicity in CAR T
John Rossi • 12 Sep 2018
View All Videos

Podcasts

View all
The need for more effective first-line therapies in MDS
Myeloma 2022: day two highlights
The promise of CAR-T therapy in CLL and challenges in the field
T-cell engagers in multiple myeloma: current challenges and future outlooks

Editorial Board

Ulrich Jäger
MD
Medical University of Vienna
Yi Lin
MD, PhD
Mayo Clinic
Christian Chabannon
MD, PhD
Paoli-Calmettes Institute
Frederick Locke
MD
H. Lee Moffitt Cancer Center & Research Institute
Mazyar Shadman
MD, MPH
Fred Hutchinson Cancer Research Center

The CAR-T & Cellular Therapy Focus on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company) and Legend Biotech.

These supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The CAR-T & Cellular Therapy Focus, please contact us.

VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals